Comparative Pharmacology
Head-to-head clinical analysis: E MYCIN versus ERYC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E MYCIN versus ERYC.
E-MYCIN vs ERYC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation of peptidyl-tRNA. It may also act as a motilin receptor agonist, enhancing gastrointestinal motility.
Erythromycin acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation step.
250-500 mg orally every 6 hours or 500 mg every 12 hours; maximum 4 g/day.
250-500 mg orally every 6 hours or 333-500 mg orally every 8 hours; maximum 4 g/day.
None Documented
None Documented
1.5-2 hours in adults with normal renal function; prolonged to 4-6 hours in severe hepatic impairment; no significant change in renal impairment due to minimal renal clearance.
2–4 hours in adults with normal renal function; prolonged to 4–8 hours in severe hepatic impairment; does not significantly change in renal failure.
Primarily hepatic metabolism and biliary excretion with significant enterohepatic circulation; approximately 2-15% excreted unchanged in urine; 10-40% excreted in feces via bile; less than 1% eliminated as unchanged drug in feces from unabsorbed drug.
Primarily biliary excretion of unchanged drug (60–80%); renal excretion accounts for 10–15% of an oral dose, with minimal fecal elimination (<5%).
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic